TW's Take: good data as INAB continues to show efficacy in a very difficult disease. 92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with the standard-of-care regimen (Stupp...
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28th to...
TW's Take: INAB's programs continue to put forth excellent data, albeit early stage in this case. - Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue - Gamma-delta nsCAR platform emerging as an...
TW's Take: INAB continues to demonstrate strong science backing their gamma-delta T Cell programs. New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T cell CAR (nsCAR) platform candidate targeting CD-33 and CD-123 will be presented. The platform has...
TW's Take: nice endorsement of IN8's therapy. No new news in this article, however. Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive cellular therapy NEW YORK, Feb. 14,...
TW's Take: Positive data post yesterday's financing is a great set up for INAB. Durable complete remission (CR) achieved in 100% of treated patients, including high-risk and relapsed acute myeloid leukemia (AML) patients and those who had failed multiple...
TW's Take: solid deal removes the overhang and enables them to get more funding in the future without needing to go to market. Some serious dilution but the stock is now reset and poised to do very well as...
TW's Take: Solid progress with more data expected in December. IN8bio continues to execute but the balance sheet remains an issue and partnering has been elusive to date. All patients treated with INB-200 who completed mandated doses to date...
TW's Take: INAB's programs are showing great early-stage efficacy. Getting a late-breaking poster slot is proof that more, high-quality data is coming from IN8bio. Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200 ...
TW's Take: data on Nov. 17th will likely be compelling. INAB continues to keep patients alive and progression free far longer than expected. Data demonstrate the ability of single and repeat doses of INB-200, DeltEx drug-resistant immunotherapy (DRI) gamma-delta...
TW's Take: while early stage, allogeneic gamma-delta T-cells would be a very big deal. INAB continues to execute on their vision. This data represents a step forward in developing next-generation ‘off-the-shelf’ iPSC derived gamma-delta T cells. Our proprietary expansion...
TW's Take: more positive data. INAB is executing and patients continue to do very well on their drugs. New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies; updated data on...
TW's Take: Solid progress from INAB in this very promising therapy. Enrollment is now open in the company-sponsored Phase 2 clinical trial of INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM). Enrollment completed in the dose escalation phase...
TW's Take: patients continue to see progression-free survival far in excess of expectations. The presentation will continue to highlight this fact. INAB is executing on their business. NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a...
TW's Take: All systems firing for INAB as they look to get more interest in their programs which are doing well despite the share price. Management presentations will highlight IN8bio’s clinical and scientific programs, including upcoming data releases at...
TW's Take: positive execution on their business strategy which positions them even better for potential partnering activity. ~ Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to encompass Chimeric Antigen Receptor T-cell (CAR-T) and...
TW's Take: State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative gamma-delta T cell therapies The new site supports IN8bio’s commitment to develop a strong biotechnology presence in the Birmingham region NEW...
TW's Take: 100% exceeding PFS with dose response and minimal toxicity is all anyone could ask for from this program. Next up for INAB is a partnership, which would be a major catalyst. 100% of treated patients (n=8) to...
TW's Take: INAB is looking to partner their programs and the strong results in conjunction with TMZ, the standard of care in many cases, should provide strong impetus to bring partners to the table. Preclinical results showcase the potential...
TW's Take: More positive data that pulls in another possible avenue for partnering. Preclinical data demonstrates that gamma-delta T cells have the ability to target other solid tumors such as ovarian cancer, supporting the development of these technologies outside...
TW's Take: obviously good data with an oral presentation, INAB continues to kick butt in all their clinical programs. NEW YORK, (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies,...
TW's Take: simply outstanding data from this program. While the balance sheet remains an issue, the value being created here is substantial and we could be in for a long run in the stock once they get more cash...
TW's Take: more solid progress from INAB. The disconnect between the valuation and the success the science demonstrates continues to grow. NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing...
TW's Take: more positive news from INAB which appears to be very successful with all their programs to date. NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta...
TW's Take: yet more very positive data from INAB. As more patients get dosed in trials, this is setting up to be a very successful platform opportunity. Expect to see a partnership sometime in the near future. NEW YORK, March...
TW's Take: Exciting data that should help drive important partnering conversations for INAB with potential large pharma partners. NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, announced...
TW's Take: Gamma-Delta T-Cells is a very hot space and IN8bio is proving to be a leader here. The stock is dramatically undervalued relative to competitors with better data. The potential here is very, very large if they continue...
TW's Take: expecting good news from their GBM program this coming week before they start presenting to investors in San Francisco. NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing...
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.